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ABSTRACT
Multiple myeloma (MM) is a fatal and incurable hematological malignancy thus
new therapy need to be developed. Cold atmospheric plasma, a new technology
that could generate various active species, could efficiently induce various tumor
cells apoptosis. More details about the interaction of plasma and tumor cells need
to be addressed before the application of gas plasma in clinical cancer treatment.
In this study, we demonstrate that He+O2 plasma could efficiently induce myeloma
cell apoptosis through the activation of CD95 and downstream caspase cascades.
Extracellular and intracellular reactive oxygen species (ROS) accumulation is essential
for CD95-mediated cell apoptosis in response to plasma treatment. Furthermore, p53
is shown to be a key transcription factor in activating CD95 and caspase cascades.
More importantly, we demonstrate that CD95 expression is higher in tumor cells
than in normal cells in both MM cell lines and MM clinical samples, which suggests
that CD95 could be a favorable target for plasma treatment as it could selectively
inactivate myeloma tumor cells. Our results illustrate the molecular details of plasma
induced myeloma cell apoptosis and it shows that gas plasma could be a potential
tool for myeloma therapy in the future.

accumulation of malignant plasma cells (PCs) in the bone
marrow (BM) of patients, results in the production of
monoclonal immunoglobulin (also known as ‘M-protein’)
and substantial immune-suppression and end-organ

INTRODUCTION
Multiple myeloma (MM), the second most
common hematological malignancy characterized by the
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damage such as anemia, thrombocytopenia, renal failure,
and bone disease [1]. In nonrandomized MM clinical
trials, high-dose chemotherapy is recommended with
an autologous transplant, which results in the highest
response rates [2, 3]. However, despite great progress
in novel anti-myeloma drugs and therapies, most of the
patients relapse and become resistant to chemotherapy
[4], which makes MM a fatal and incurable hematological
malignancy. Regulation of redox homeostasis is one
strategy for cancer treatment, as long-term ROS
simulation plays an important role in cancer development
through oxidative DNA damage and gene mutations [5,
6]. Radiation and several chemotherapy drugs can produce
extracellular and intracellular ROS, thus disrupting redox
homeostasis, which can induce tumor cell apoptosis [7, 8].
Cell apoptosis are mainly conducted by three pathways:
mitochondrial pathway, extrinsic pathway such as death
receptors (DR) and tumor necrosis factor receptor (TNF),
endoplasmic reticulum (ER) stress pathway [9, 10]. In this
study, we investigated whether CD95, a key death receptor
that is pivotal for the induction of tumor cell apoptosis and
is a major target in cancer therapy [11, 12], is involved
in plasma induced cell apoptosis. It was reported that
CD95 is widely expressed in patient myeloma cells
and myeloma cell lines [13, 14]. Anti-CD95 antibodies
could directly target CD95; however, only some samples
exhibited cell apoptosis [15]. ROS accumulation could
also regulate CD95, thus activating CD95-mediated
tumor cell apoptosis [16, 17]. In addition to radio- and
chemotherapies, a new technology called cold atmospheric
plasma (CAP) could provide controllable exogenous
reactive oxygen and nitrogen species [18, 19]. Plasmas are
ionized gases, comprising a complex mixture of charged
particles, neutral gas molecules, UV radiation, electric
fields and reactive species [20]. Owing to technological
advancements, it is now possible to generate plasmas at
atmospheric pressure and room temperature (e.g., CAP),
which enables the application of plasma in a range of
biomedical processes such as wound healing, disinfection
and cancer treatment [21, 22]. Most plasma devices could
be divided into two types: plasma jet and Dielectric
Barrier Discharger (DBD) [23–25]. CAP is a favorable
source of reactive oxygen and nitrogen species, and it has
been found to be efficient for killing tumor cells in various
types of cancer, including lung cancer, leukemia, intestinal
cancer, melanoma, cervical cancer, glioma, pancreatic
cancer et al. [26–29]. The induction of apoptosis in cancer
cells has been widely reported, and the mechanism of
plasma-induced apoptosis is increasingly being understood
[30–32]. It is reported that plasma could affect various
cancer cell signaling such as AGP-ROS, MAPK, p53 and
PI3K/AKT pathway and induced cell apoptosis [33]. In
this study, we first demonstrated that CD95 was involved
in plasma-induced cancer cell apoptosis. Up-regulation
of CD95 was positively correlated with the accumulation
of extracellular and intracellular ROS. By chromatin
www.oncotarget.com

immune-precipitation (ChIP) assay, we demonstrated that
p53, which was up-regulated by plasma treatment, could
bind to the CD95 promoter region and increase CD95
expression, resulting in the activation of caspase signaling
and induction of apoptosis. Furthermore, because of the
differential expression of CD95 in normal and myeloma
cells, plasma could selectively inactivate tumor cells
in myeloma cell lines and patient samples. Our results
provide a new strategy for potential myeloma therapy by
targeting CD95 with cold atmospheric plasma.

RESULTS
Characteristics of plasma generation
He plasma was generated at the voltage of 10 kHz/8
kV with a He gas flow of 2 SLM. Additional O2 was mixed
in to produce more ROS. (Figure 1A and 1B) show the
structure of the plasma jet and photographs of He/He+O2
plasmas. Additional O2 decreased the intensity of the plasma
and changed the plasma plume from purple to gray. (Figure
1C) shows the corresponding applied voltage and current
during He+O2 plasma generation. To investigate the different
reactive species in the plasma, we used a spectrometer to
measure the emission spectra. As shown in (Figure 1D), there
were several spectral lines (e.g., OH (A) 309 nm, N2 (C) 337
nm, N2+ (B) 391 nm, He (3s3S1) 706 nm and O (3p5P) 777
nm) present in the plasma and they were marked according to
the literature [34, 35]. The intensity of the plasma components
gradually decreased when the percentage of mixed O2 was
increased from 0% to 1% (Figure 1E).

Decrease in cell viability and induction of
apoptosis after plasma treatment for different
durations
We treated LP-1 MM cells with CAP and
investigated the biological effects of plasma. CellTiterGlo assay showed that the cell viability 24 h and 48 h
after He plasma treatment gradually decreased in a timedependent manner (Figure 2A). Next, we added O2 to
He to generate He+O2 plasma, which could produce
more ROS. We added O2 at 0.2%, 0.5% and 1% of the
total mixture. Because O2 is a electronegative gas, a
mixture with greater than 1% of O2 will eliminate plasma
generation. (Figure 2B) shows the cell viability 24 h after
the application of the various compositions of He+O2
plasma. The addition of 0.2% O2 didn’t promote LP-1
cell death compared to He+0% O2, and the cell viability
of He+0.5% O2 treatment was sharply decreased and
much lower than other groups when the treatment time
was over 30 s. Referring to the intensity and stability
of the plasma (Figure 1E), we chose the He+0.5% O2
plasma for use in our following experiments. (Figure 2C)
shows apoptosis in the cells detected by flow cytometry
24 h after He+0.5% O2 treatment.
18003
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Figure 1: Characteristics of the plasma generation system. (A) Schematic representation of the plasma jet. (B) Photographs of

He plasma and He+O2 plasmas. (C) Monitoring of the applied voltage and current during He+O2 plasma generation. (D) Emission spectra
of different He+O2 plasmas detected by the spectrometer. Some unique spectral lines (OH, N2, He and O) in the He+0.5% O2 plasmas are
marked. (E) The intensity of several characteristic spectral lines are shown with varying O2 percentage in the working gas.

Figure 2: Cell viability and apoptosis after plasma treatment for different durations. (A) Analysis of cell viability 24 h
and 48 h after He plasma treatment for different durations. (B) Analysis of cell viability 24 h after He+O2 plasma for different
durations. (C) Cell apoptosis analyzed by flow cytometry after He+0.5%O2 plasma treatment for 0.5, 1, and 2 min.

www.oncotarget.com
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Changes in mitochondrial membrane potential
(MMP), lysosomal leakage and activation of the
caspase cascades after plasma treatment

blotting results showed that caspase3/8/9 (32 kD, 31 kD
and 18 kD, respectively) were all increased after plasma
treatment (Supplementary Figure 1). Cleaved caspase8
(43 kD and 41 kD) exhibited a significant increase,
while that of caspase8 (55 kD) remained the same after
plasma treatment. The level of caspase9 (47 kD) was
slightly increased after plasma treatment. These results
indicated that caspase3 and caspase8 were the main factors
activating the apoptotic process.

Changes in MMP (JC-1 staining) are known
indicators of early apoptosis [11]. By fluorescence
microscopy, we showed that the red fluorescence (JC-1
aggregates) declined after He+O2 plasma treatment (Figure
3A), which was further confirmed by flow cytometry
(Figure 3B). Lysosomal leakage assay (stained by lucifer
yellow dye) showed that plasma treatment resulted in the
release of the dye from lysosomes into the cytoplasm,
generating diffuse green staining instead of the punctate
pattern seen in the control (Figure 3C). Since the activation
of caspase cascades plays a central role in apoptosis, we
investigated enzyme activity of caspase3/8/9 at 3 h and
6 h after He+O2 plasma treatment. The results showed
that the enzyme activity of caspase3/8 was increased
by plasma treatment, while that of caspase9 increased
slightly only at 6 h after treatment (Figure 3D). Western

Analysis of apoptosis-related protein array after
He+O2 plasma treatment
To elucidate the molecular mechanism of plasmainduced cell apoptosis, a human apoptosis protein array
containing 35 apoptosis-related proteins was used 24
h after He+O2 treatment for 60 s. As shown in (Figure
4A), the level of cytochrome C was decreased, while
that of CD95 and phospho-p53 was significantly
increased by plasma treatment. As CD95 is a key cell

Figure 3: MMP, lysosomal leakage and caspase activation induced by plasma treatment. (A, B) LP-1 cells stained with
a reporter dye, JC-1, for mitochondrial condition are detected by (A) fluorescence microscopy and (B) flow cytometry. (C) Analysis of
lysosomal leakage in LP-1 cells indicated by fluorescence staining with Lucifer yellow after plasma treatment for 0.5, 1 and 2 min. (D) The
activity of caspase3/8/9 was measured with a Caspase Colorimetric Assay Kit 3 h and 6 h after plasma treatment.
www.oncotarget.com
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ROS accumulation is essential for CD95mediated cell apoptosis by plasma treatment

death receptor (DR), we confirmed CD95 expression
by flow cytometry after plasma treatment. The results
showed that CD95 was up-regulated in a timedependent manner by He+O2 treatment (Figure 4B).
These results indicated that CD95 might be involved in
plasma-induced cell apoptosis.

As ROS produced by plasma are considered to play
an important role in biological processes, we investigated
extracellular and intracellular levels of ROS after He+O2
plasma treatment. Extracellular ROS level was significantly
increased immediately after plasma treatment, while at
24 h and 48 h after treatment, it was only slightly higher
than the level before treatment (Figure 6A). NAC, which
is a general ROS scavenger, could efficiently eliminate
extracellular ROS accumulation at a final concentration of
5 mM or 10 mM. Meanwhile, NAC alone (5 mM or 10
mM) had no cell toxicity on LP-1 cells as no reduction of
cell viability was detected after adding NAC for 24 h and 48
h. Intracellular ROS was detected by flow cytometry, and
the results showed that there was no difference immediately
after plasma treatment, or in a short time (3 h and 6 h)
after plasma treatment (data not shown), but the level was
significantly increased 24 h after plasma treatment (Figure
6B). NAC not only eliminated extracellular ROS but also
blocked the intracellular ROS accumulation despite the
various durations of plasma treatment. Cell viability assay
revealed that preventing ROS accumulation by NAC could
reduce plasma-induced cell apoptosis measured at 0 h,
24 h and 48 h (Figure 6C). Furthermore, elimination of
extracellular and intracellular ROS accumulation by NAC
prevented the increase in the expression of CD95 by plasma
treatment measured by flow cytometry, real-time PCR and
western blotting (Figure 6D).

Down-regulation of CD95 reduced plasmainduced cell apoptosis
We used CD95-targeting short interfering RNAs
(siRNA) to down-regulate CD95 expression and assessed
the effect of plasma on cell apoptosis. 48 h after siRNA
transfection, we detected CD95 expression by flow
cytometry, real-time PCR and western blotting. As
shown in (Figure 5A), the percentage of CD95+ cells was
decreased after siRNA transfection. CD95 expression at
mRNA and protein levels was also decreased compared
to that of the control. The percentage of CD95+ cells
(Figure 5B) and corresponding cell viability (Figure
5C) after CD95 knockdown and plasma treatment
was investigated. CD95 expression and cell viability
was negatively correlated. Down-regulating CD95
could reduce cell viability reduction caused by plasma
treatment. By Annexin-V/PI staining, we further
confirmed that compared to the control, down-regulation
of CD95 could reduce cell apoptosis induced by He+O2
plasma treatment for 1 min (Figure 5D). These results
indicated that CD95 is involved in He+O2 plasmainduced cell apoptosis.

Figure 4: Analysis of apoptosis-related protein array and CD95 expression after plasma treatment. (A) Cell apoptotic
apoptosis-related protein array detection was performed 24 h after He+O2 plasma treatment for 1 min. (B) CD95 expression was measured
by flow cytometry 24 h after He+O2 plasma treatment for 0.5 min, 1 min and 2 min. IgG was used as the isotype control of CD95.
Percentage of CD95 expression and MFI ratio were expressed in M±SD. * indicates p<0.05, ** indicates p<0.01
www.oncotarget.com
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p53 mediated CD95 up-regulation in plasmainduced apoptosis

reported that p53 was activated in response to plasma
treatment and promoted cancer cell apoptosis [36–39]. We
wondered whether p53 could regulate CD95 expression
thus activating the downstream caspase pathway. PFT-α,
a p53 inhibitor, was used in this study and could reduce
cell apoptosis by plasma treatment (Figure 7A). Western

Using the apoptosis-related protein array we also
detected an increase in phospho-p53 level after He+O2
plasma treatment. In addition, several studies had

Figure 5: Down-regulation of CD95 expression by siRNA reduced plasma-induced cell apoptosis. (A) CD95 expression

detected by flow cytometry, real-time PCR and western blotting after siRNA-mediated knockdown for 48 h. IgG is the isotype control. Con
indicates transfection of control scramble siRNA compared to CD95-targeting siRNA. (B, C) CD95 expression (B) and corresponding cell
viability (C) 24 h after plasma treatment for 0.5 min, 1 min and 2 min. Con- and Con+ groups were transfected with control scramble siRNA
and treated without or with He+O2 plasma. The siRNA+ group represents cells treated with He+O2 plasma after knockdown of CD95 by
siRNA. (D) Cell apoptosis was detected 24 h after He+O2 plasma treatment for 1 min following transfection. * indicates p<0.05.
www.oncotarget.com
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Differential expression of CD95 and sensitivity of
normal and myeloma cells to plasma treatment
in cell lines and clinical samples

blotting showed that NAC and PFT-α could both decrease
the expression of phospho-p53. Meanwhile, inhibition
of p53 prevented the up-regulation of CD95 expression
and the activation of caspase 3/8/9 detected by western
blotting (Figure 7B). Since p53 is a transcription factor,
using ChIP assay, we investigated whether p53 could
bind to the promoter region of CD95 to regulate CD95
expression. Indeed, our ChIP results demonstrated that
phospho-p53 could bind to the promoter region of CD95
mRNA and regulate mRNA expression, as a clear band
was detected by electrophoresis in the sample treated
with He+O2 plasma (Figure 7C). He+O2 plasma increased
the binding of p53 to the CD95 promoter region (-1454
upstream of the CD95 transcription initiation site)
compared to the control and activated CD95 mRNA
expression (Figure 7C). The details of sequence analysis
are list in Supplementary Files (sequences analysis.doc).

Since we demonstrated that CD95 is an important
target in plasma-induced cell apoptosis, we wondered
whether normal and tumor cells express different levels
of CD95 and if the cells have differential sensitivity
to plasma treatment. As shown in (Figure 8A), LP-1
myeloma cells have a higher expression of CD95
compared to normal cells (marrow stromal cells, MSC)
detected by flow cytometry, real-time PCR and western
blotting. Meanwhile, viability assay revealed that MM
tumor cells were more sensitive to plasma treatment
that MSC normal cells (Figure 8B). Similar to the data
from MM cell lines, the tumor cells derived from MM
patients displayed higher CD95 expression compared to

Figure 6: Extracellular and intracellular ROS, cell viability and CD95 expression were measured after He+O2 plasma
treatment with ROS scavenger (NAC). (A) Extracellular ROS level detected with a microplate reader at 0 h, 24 h and 48 h after
plasma treatment for 0.5, 1 and 2 min with or without NAC. (B) Intracellular ROS level detected with a flow cytometer 24 h after plasma
treatment without (above) or with (below) NAC. (C) Cell viability measured by CellTiter-Glo assay at 0 h, 24 h and 48 h after plasma
treatment for 0.5, 1 and 2 min with or without NAC. (D) CD95 expression was detected by flow cytometry (left) and real-time PCR
(middle) 24 h after He+O2 treatment and by western blot (right) 48 h after plasma treatment with or without NAC.
www.oncotarget.com
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DISCUSSION

normal control detected by flow cytometry (Figure 8C)
and western blotting (Figure 8D). In addition, the tumor
cells showed a significant reduction in cell viability
after plasma treatment compared to the normal control
(Figure 8E). By fluorescent in situ hybridization (FISH),
we detected several common genetic alterations in MM
that could predict the prognosis of MM patients. Patients
with RB1 deletion and 13q14 deletion were considered
to have moderate prognosis, while patients with 1q21
amplification and 14q32 translocation were considered
to have poor prognosis [35] (Supplementary Table 2).
Interestingly, tumor cells derived from patients with poor
prognosis were more sensitive to plasma treatment than
those from patients with moderate prognosis (Figure 8F).
Furthermore, we analyzed the viability differences of
tumor cells and normal cells after plasma treatment and
found that for the samples from patients with moderate
prognosis, shorter plasma treatment (30 s) showed better
selectivity, while that with poor prognosis, longer plasma
treatment (60 s) showed better selectivity (Figure 8G).
These data may provide useful treatment parameters for
clinical therapy.

Plasmas are a mixture of charged particles, neutral
gas molecules, UV radiation, and reactive species, among
which, the reactive species were considered to be the
most important factors for biological effects [40]. The
temperature of plasma in our study is around 30°C, which
has little heat effect on cells as cells were further cultured
at 37°C in the incubator. This plasma jet generation
system was used in our previous studies and characters
of the plasma generation and electronic parameters were
well illustrated in our previous works, including the
distribution of various species by emission spectrum and
mass spectrometer [28]. We also demonstrated that plasma
jet could generate aqueous reactive species including OH,
H2O2, O2- and nitrite (HNO2/NO2-), among which the longlived species (H2O2) could reach to μM concentration
level [41, 42]. In this study, we found for the first time
that CD95/FAS is a pivotal target that induces cancer cell
apoptosis in response to plasma treatment. The activation
of CD95 was positively correlated with the accumulation of
extracellular and intracellular ROS. Interestingly, there was

Figure 7: Involvement of p53 in CD95-mediated cell apoptosis by He+O2 plasma treatment. (A) Analysis of cell viability

after plasma treatment for 0.5, 1 and 2 min with or without NAC or PFT-α (p53 inhibitor). (B) Western blot analysis of phospho-p53,
caspase3/8/9 and CD95 expression after plasma treatment. NAC and PFT-α indicates that the ROS scavenger and p53 inhibitor were added
respectively before plasma treatment for 2 min. (C) Interaction of p53 and CD95 promoter region in response to plasma treatment. The top
panel shows the illustration of the CD95 promoter region and p53 binding site. The bottom panel shows the results of ChIP assay for p53
and CD95 promoter detected by RT-PCR and real-time PCR. * indicates p<0.05.
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a time lag between the increase in extracellular ROS and
the accumulation of intracellular ROS, as the former was
significantly increased immediately after plasma treatment,
but the latter could only be detected 24 h after plasma
treatment. Only some small molecules such as H2O2 can
catalytically permeate cells with the aid of the membrane
transporters [43]. However, other ROS, such as OH radicals,
cannot pass through the cell membrane owing to their high
reactivity. Therefore, most of the intracellular ROS are
generated inside the cells through signal transduction from
the extracellular ROS. This can explain the time lag for the
detection of intracellular ROS 24 h after plasma treatment.
However, details regarding signaling transduction by ROS
are mostly unknown because of the high reactivity and
extreme short life of ROS.
We used He+O2 plasma in our study, as the addition
of O2 can increase the production of ROS by plasma
and cause more cell death. From the emission spectra,

we confirmed that the He+O2 plasma generated more
ROS such as OH, O777 and O845 compared to the He
plasma. However, higher percentage of O2 in the He
mixture can decrease plasma intensity or even inhibit
plasma generation. Considering the plasma intensity and
stability (monitored using electric current) along with its
effects on cell viability, we chose the plasma generated
from He+0.5% O2 for our subsequent experiments.
Several studies also reported that He+O2 plasma could
substantially reduce cancer cell viability [44, 45].
ROS production by other approaches (such as
chemo-drugs) can also result in cell apoptosis through
up-regulation of CD95, which has been reported in the
literature [16, 46]. Here, we demonstrated that ROS
production by plasma treatment, could lead to cell
apoptosis via the activation of CD95 and downstream
caspase cascade. By down-regulation of CD95, we
confirmed that CD95 is a major executor in plasma-

Figure 8: Differential CD95 expression and sensitivity to plasma of cell lines and patient samples. (A) CD95 expression

in MM tumor cells and normal cells (MSC) detected by flow cytometry, real-time PCR and western blotting. (B) Sensitivity of tumor and
normal cells to plasma treatment assessed by cell viability assay. (C, D) CD95 expression detected by flow cytometry (C) and western
blotting (D) in a representative patient sample. (E) Sensitivity of tumor and normal cells derived from patients assessed by cell viability
assay 24 h after plasma treatment. (F) Sensitivity of MM tumor cells derived from patients with moderate and poor prognosis (analyzed
by FISH) in response to plasma treatment, (G) Difference in viability of tumor and normal cells after plasma treatment in samples from
patients with moderate and poor prognoses. * indicates p<0.05, ** indicates p<0.01.
www.oncotarget.com
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induced cell apoptosis. However, whether the extracellular
ROS can directly affect CD95 to activate the caspase
cascade remains unknown. By far, computer modeling
could be a way to understand the interaction of small
molecules (especially with high reactivity) with biological
molecules [47]. In our study, we could only demonstrate
with an ROS scavenger that ROS accumulation is
necessary for CD95 activation by plasma. Interestingly,
we also detected an increase in phospho-p53 in the protein
array. The tumor suppressor protein p53 is a redox-active
transcription factor that regulates various downstream
targets and can induce cell apoptosis [48]. As a secondary
messenger, ROS can activate p53 expression, thereby
regulating downstream targets of p53 [49, 50]. Zalcenstein
et al. reported that in H2O2-treated human cells, one-third
of the highly responsive genes were targets of p53 [51].
Therefore, we investigated whether CD95 up-regulation
in response to plasma treatment was mediated by p53.
Using anti-phospho-p53 antibodies, we isolated the
DNA fragments bound to p53. With well-designed PCR
primers against the CD95 promoter region, we observed a
significant increase in interaction between p53 and CD95
promoter after He+O2 plasma treatment. Furthermore, p53
inhibitor could reduce the up-regulation of CD95 induced
by plasma treatment. Hence, for the first time, we reported
the details of ROS/p53/CD95/caspase activation with a
He+O2 plasma treatment system. By ChIP assay, Ruiz et
al. reported the presence of p53-mediated up-regulation of
CD95 gene expression upon genotoxic treatment in human
breast tumor cells, which was consistent with our results
showing that p53 could interact with CD95 promoter,
thereby regulating its mRNA expression [52].
Unlike radiation, which can penetrate deep inside
tissues, CAP has limited penetration. For topological
treatment such as in dermatology and wound healing,
direct plasma treatment could be applied. For other internal
diseases, injection of plasma-activated medium (PAM)
could be used. Many studies have reported the induction
of cell death by PAM in various tumor cells such as
glioblastoma cells, lung adenocarcinoma cells and ovarian
cancer cells [53–56]. Understanding the mechanism of
plasma-induced myeloma cell death will provide a better
strategy for future clinical trials investigating the injection
PAM into the blood or bone marrow. However, before gas
plasma could be applied in clinical cancer treatment, the
safety should also be concerned. It is revealed that plasma
treatment could selectively induce tumor cells apoptosis
but had little cytotoxicity on normal cells [53, 57]. Our
previous study demonstrated that oral lavage of PAW
treatment on immuno-deficient nude mice showed no
significant safety problems without lethal effect and other
acute toxicity [58]. Besides, some gas plasma devices
have been applied in clinical trials, especially in wound
healing [59, 60]. Some products in plasma medicine have
been certified by the U.S. Food and Drug Administration
(FDA) [61], although they all limited in skin treatment. In
www.oncotarget.com

this study, we detected that the myeloma cells were more
sensitive to plasma treatment compared to the normal
stromal cells (MSC). Since we demonstrated that CD95
is critical in plasma-induced apoptosis, we analyzed the
differential expression of CD95 in cancer and normal
cells. We found that CD95 expression was higher in
tumor cells than in normal cells in both MM cell lines
and clinical samples. Interestingly, we predicted prognosis
by FISH to detect genetic alterations and found that
cells from MM patients with poor prognosis were more
sensitive to plasma treatment. This may partly be because
patients with poor prognosis have a higher percentage
of MM tumor cells in the bone marrow. These results
further confirmed that CD95 could be a potential target
for myeloma treatment with gas plasma.
In conclusion, we demonstrated that He+O2 plasma
could efficiently induce cell apoptosis through the
activation of CD95 and downstream caspase cascades.
Extracellular and intracellular ROS accumulation was
essential for CD95-mediated cell apoptosis in response
to plasma treatment. Furthermore, p53 was shown to
be a key transcription factor in activating CD95 and
caspase cascades. Supplementary Figure 2 illustrates the
schematic representation of He+O2 plasma-induced cell
apoptosis mediated by ROS/p53/CD95/Caspase signaling.
Meanwhile, we demonstrated that CD95 expression was
higher in tumor cells than in normal cells in both MM cell
lines and MM clinical samples, which suggests that CD95
could be a favorable target for plasma treatment as it could
selectively inactivate myeloma tumor cells.

MATERIALS AND METHODS
Plasma generation system
The cold atmospheric plasma used in this study was
generated using a plasma jet described in our previous
study [62]. And the schematic diagram of the device
structure is shown in Figure 1A. A 1 mm stainless steel
needle as a powered electrode enclosed in a length of 6 cm
and inner and outer diameters of 4 mm and 6mm quartz
tube respectively, which is 15 mm above the top of quartz
tube. A length of 10mm copper sheet was wrapped around
the quartz tube at a distance of 10 mm from the nozzle
end serves as the ground electrode. The plasma generation
system included a gas flow controller, high-voltage power
supply, oscilloscope, and plasma jet. A gas flow of 2 SLM
was used for He at 10 kHz/8 kV. Additional O2 was added
in the gas flow to generate He+O2 plasma for more ROS
production.

Cell culture conditions
The LP-1 multiple myeloma cells and MSC cells
were used as control cells as described in our previous
study [62]. These suspension cells were grown in
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Oncotarget

Roswell Park Memorial Institute (RPMI) 1640 medium
supplemented with 10% fetal calf serum, 100 U/mL
penicillin, and 50 μg/mL streptomycin (Corning, Ithaca,
NY, USA). The cells were cultured at 37°C in an incubator
(Thermo Scientific, Waltham, MA, USA) containing 5%
CO2. The medium was refreshed 24 h before performing
experiments, then 6 × 104 cells/ well in 100 μL medium
were seeded on 96-well plate and 2 × 105 cells/ well
in 300 μL medium were seeded on 24-well plate when
performing the plasma treatment experiments.

at a final concentration of 2.5 μg/mL. The mixture was
incubated for 20 min at 37°C in an incubator containing
5% CO2. After washing with ice-cold 1× JC-1 staining
buffer, the cells were resuspended in 0.5 mL staining
buffer. The stained cells were observed by fluorescence
microscopy (BX53; Olympus, Japan), following the step
of concentrating the suspensions onto microslides by
centrifugation for 15 min at 750 rpm with a cytocentrifuge
(Cytopro; Wescor, Logan, UT, USA), as well as analyzed
directly by flow cytometry (BD). Valinomycin-treated
cells were used as positive control, because valinomycin
can dissipate the MMP in LP-1 cells.

Optical emission spectroscopy
Emission spectra of the plasma were measured using
a UV/Visible spectrometer (Maya pro 2000, Ocean Optics,
China) within a wavelength range of 200-800 nm. The
emission spectra of He plasma with different percentage
of O2 were analyzed in the vertical plane of the plasma jet.
Because the intensity of light is highest at the point where
the plasma touches air, the optical probe was mounted at
the nozzle of the plasma jet generator, which guarantees a
clear spectrum of particles in the plasma plume.

Stability of lysosomal membrane
Lucifer yellow CH (Sigma-Aldrich, 2 mg/ml
stock solution in PBS), which indicates the stability and
leakage of lysosomes, wasadded to LP-cells at a final
concentration of 100 μg/ml and incubated overnight. Then,
the cells were washed three times with PBS and seeded
on a 24-well plate. Next, the stained LP-cells were treated
with plasma for 0 min (control group), 0.5 min, 1 min and
2 min. After incubation for 24 h, cells were washed twice
and concentrated onto a glass slide using a cytocentrifuge
(Cytopro; Wescor, Logan, UT, USA) for observation of the
cell status via fluorescence microscopy (BX53; Olympus,
Japan).

Cell viability assay
A Cell-Titer-Glo® luminescent cell viability assay
kit (Promega, Madison, WI, USA) which based on the
production of ATP in viable cells was used to measure
cell viability. 100 μL of samples and 100 μL of Cell-TiterGlo® reagent were added to the opaque-walled multi-well
plate, then the plate was incubated at room temperature
for 10 min after mixing for 2 min on an orbital shaker. The
luminescence was determined using the microplate reader
((Thermo Scientific Varioskan Flash, Waltham, MA, USA)
with the protocol of “luminometric” measurement.

Human apoptosis array kit
Human Apoptosis Array Kit (R&D Systems,
Minneapolis, MN, USA), which can detect 35 different
proteins like Bad, Bax, BCL-2, Fas and HSP27 etc.,
was purchased for analyzing the expression profiles of
apoptosis-related proteins induced by plasma treatment
for 1 min. After 24 h incubation, LP-1 cells treated with or
without plasma were rinsed with PBS and solubilized in
lysis buffer 17 for 30 min at 4°C, followed by centrifuging
at 14,000 rpm for 5 min, then the supernate was transferred
and protein concentration was quantified. Cell lysates with
300 μg protein was added and incubated overnight at 4°C
after blocking membrane with array buffer 1. Following
washing each array with 1×wash buffer for 10 min twice,
1.5 mL of detection antibody cocktail was added and
incubated 1 h on a rocking platform shaker. Then the array
was washed and 2.0 mL of Streptavidin-HRP was pipetted
into each well and incubated for 30 min. After washing
each array, the protein spots were visualized using Chemi
Reagent Mix by Chemi-Doc-it Imaging System (UVP,
Upland, CA, USA) and the intensity was determined by
ImageJ Version 1.45 software.

Cell apoptosis assessment
We used Annexin V and PI (BioLegend, San
Diego, CA, USA) double staining for the detection of cell
apoptosis by flow cytometry. After treatment with plasma
for 24 h, cells were washed twice with cell staining buffer
and resuspended in 50 μL Annexin V binding buffer.
Next, 2 μL Annexin V-APC and 2.5 μL PI were added
and incubated for 15 min at room temperature in the
dark. Then, 400 μL Annexin V binding buffer was added,
followed by flow cytometry (Accuri C6; BD, USA).

Detection of MMP
Mitochondria staining kit (Sigma-Aldrich, Saint
Louis, MO, USA), which contains the cationic lipophilic
dye JC-1, was used to detect changes in the MMP in LP-1
cells after plasma treatment following the manufacturer’s
instruction. After incubation for 24 h, 1 mL LP-1 cell
suspension (1×106/mL) was collected from each treatment
and mixed with 1 mL prepared staining solution with JC-1
www.oncotarget.com

Analysis of CD95 expression by flow cytometry
The expression of CD95 was assayed by
immunofluorescence staining using flow cytometry. In brief,
LP-1 cells were harvested and washed twice with PBS.
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Western blot

Then, the cells were incubated with 5 μL of CD95-FITC
(BioLegend, San Diego, CA, USA) in 50 μL PBS for 30 min
at room temperature in the dark. After that, the cells were
washed with PBS and resuspended in 400 μL PBS for flow
cytometric (C6) analysis. Mouse IgG1-FITC (Biolegend, San
Diego, CA, USA) was used as an isotype control for CD95
in this experiment. The MFI (mean fluorescence intensity)
ratio was determined as follows: MFI ratio = MFI of CD95
expression / MFI of isotype control.

After plasma treatment for 48h, cell protein was
extracted using RIPA lysis buffer (Sigma), and the
concentration was determined by BCA protein assay
kit (Sigma). Protein samples were denatured with
5×protein loading buffer at 95°C for 5min and separated
in 12.5% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) (Bio-Rad, Hercules, CA,
USA). Subsequently, proteins were transferred to 0.2
μm of polyvinylidene difluoride membranes (Millpore,
Billerica, MA, USA) at 70 V for 2.5 h. After blocking
with 5% non-fat milk for 2 h at room temperature, the
membrane was incubated with primary antibody and
then washed with TBST three times. The horseradish
peroxidase (HRP)–conjugated secondary antibodies,
goat anti-rabbit IgG and anti-mouse IgG (1:2000)
(Abgent, San Diego, CA, USA), were added and
incubated for 1h on a horizontal orbital shaker. Images
were visualized with ECL chemiluminescent substrate
(Millipore, Bedford, MA, USA) using a ChemiDoc-It
510 system (UVP, Upland, CA, USA) and protein bands
were analyzed by densitometric analysis using ImageJ
software. Primary antibody against human included
caspase-3 (1:500), caspase-8 (1:500), caspase-9 (1:500),
phospho-p53 (1:200) (Cell Signaling Technology,
Danvers, MA, USA), CD95 (1:200) (Santa Cruz, CA,
USA) and β-actin (1:1000) (Immuno Way, Newark, DE,
USA).

Transfection with siRNA
Lipofectamine 2000 was used to transfect CD95targeting siRNA into LP-1 cells to knock down the
expression of CD95 following the manufacturer’s
instructions. Briefly, at the time of transfection, 1×105
cells/well were plated in 24-well plates with culture
medium. For each sample, cells were transfected with
CD95-targeting siRNA (Santa Cruz, CA, USA) at a final
concentration of 125 nM using 6 μL of Lipofectamine
2000 reagent (Invitrogen, Carlsbad, CA, USA). A scramble
siRNA was used as control siRNA. After incubation for
48 h, cell viability and cell apoptosis were analyzed, and
CD95 expression was determined by real-time PCR, WB
and flow cytometry as mentioned. Then, the cells were
treated with plasma for further experiments.

Detection of ROS
In our experiment, CMH2-DCFDA (Invitrogen,
Grand Island, NY, USA) was used to detect ROS
concentration. Cells (1×105) were plated in 24-well plates
with 300 μL complete medium and treated with plasma for
0.5 min, 1 min and 2 min with or without 5 mM/10 mM
NAC. After 24 h, 10 μM of CMH2-DCFDA was incubated
with the LP-1 cells for 30 min at 37°C. Extracellular ROS
was measured with a microplate reader (Thermo Scientific)
with excitation/emission at 485/530 nm using the protocol
for “Fluorometric” measurement. Then, the cells were
washed three times with PBS and collected for analysis of
intracellular ROS using a flow cytometer (Accuri C6).

Real-time PCR
To quantify the relative mRNA expression
of CD95 (Fas), real-time PCR was performed after
plasma treatment (24 h later) or siRNA trasfection
(48 h later). Total RNA was extracted from LP-1 cells
using EZNA total RNA kit II (Omega Bio-Tec Inc.,
Doraville, GA, USA). After quantifying with Nano Drop
spectrophotometry (BioTek® Instruments Inc., Winooski,
VT, USA), 2 μg of total RNA was used for the synthesis
of fist strand cDNA using RevertAid first strand cDNA
synthesis kit (Thermo Scientific, Waltham, MA, USA),
which performed on Applied Biosystems Veriti™ Thermal
Cycler (Applied Biosystems, Foster City, CA, USA). All
real-time PCR reactions were set up in a 20 μL mixture
containing 1/2 volume of 2×QuantiFast SYBR Green
PCR MasterMix (Qiagen, Hilden, NRW, Germany),
0.5 μM of primer, 1 μL of cDNA templates and 8 μL of
DNAase-RNase Free water. The above reactions were run
on Bio-Rad CFX Connect™ Real-time System (Bio-Rad,
Foster City, CA, USA) and amplified with a optimized
cycling condition: 5 min at 95°C, then 10 s at 95°C
and 30 s at 60°C for 38 cycles; the melting curves were
obtained by slow heating (0.5°C/s) from 60°C to 95°C.
The primers were designed by Shenggong Company
(Shanghai, China) and the sequences were showed below:

Enzyme activity of caspase3/8/9
Caspase colorimetric assay kit (Biovision, USA) was
used to evaluate caspase activity in LP-1 cells treated with
plasma for 0.5 min, 1 min and 2 min. NAC was added to
the cells at a final concentration of 10 mM followed by 2
min plasma treatment. After incubation for 6 h and 9 h, cells
were resuspended in 50 μL cell lysis buffer and incubated
on ice for 10 min. Then, the concentration of protein in the
centrifuged supernatant was assayed. Samples with 150
μg protein in 50 μL cell lysis buffer were added to 96-well
plates and cultured with 50 μL of 10 mM DTT and 5 μL of
4 mM substrate at 37°C for 1.5 h. The absorbance was read
at 400 nm in a microtiter plate reader (Thermo Scientific).
www.oncotarget.com
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Fas forward, 5′-CCCAGAATACCAAGTGCAG-3′; Fas
reverse, 5′-GTGCATTCCTTGATGATTCCA-3′; β-actin
forward, 5′-CATGTACGTTGCTATCCAGGC-3′; β-actin
reverse, 5′-CTCCTTAATGTCACGCACGAT-3′. The
relative expression of CD95 was normalized against a
housekeeping gene of β-actin using the ΔΔCt method.

Xi’an. The basic information on these patients is listed in
Supplementary Table 1, including gender, age and blood
test results. Bone marrow samples were also obtained and
tested using Giemsa staining to measure the percentage
of MM tumor cells. MM tumor cells were sorted using
MACS (magnetic-activated cell sorting) from the bone
marrow samples. Briefly, 20 mL bone marrow (with
heparin) was centrifuged and washed with PBS and
resuspended in 7 mL of Ficoll (lymphocyte separation
medium). The cells were centrifuged at 1800 rpm for 20
min, and the middle layer was isolated for staining with
CD138-conjugated magnetic beads. After incubation
at 4°C for 15 min, the cells were washed with PBS and
sorted with MACS columns. The positively selected cells
were considered MM tumor cells, and the rest of the
cells mostly were bone marrow stromal cells that were
considered as the control group. The sensitivity treatment
of these cells to plasma was detected by a cell viability
assay, and CD95 expression was measured by flow
cytometry and western blotting.

Effect of p53 inhibitor Pifithrin-α on CD95
expression and plasma-induced cell apoptosis
LP-1 cells (1×105/well) were seeded in 24-well plates
with 300 μL RPMI 1640 medium and pretreated with 10
μM of PFT-α (Target Mol, Boston, MA, USA), which is
an inhibitor of p53, for 1 h at 37°C prior to treatment for 2
min with plasma. After incubation for 48 h, apoptosis was
examined by western blotting as previously described.

ChIP assay
ChIP assay was performed on LP-1 cells with Magna
ChIP™ A/G (Millipore; Billerica, MA, USA) following
the manufacturer’s instructions. Cells (1×106) were
treated with or without (control group) He+O2 plasma for
1 min; after incubation for 24 h, cells were collected and
fixed in 1% formaldehyde for cross-linking. The mixture
was incubated at room temperature for 10 min, and 10×
Glycine was added to quench the unreacted formaldehyde.
After incubation for 5 min, the cells were centrifuged
and washed twice with cold 1× PBS. The cell pellet was
incubated with 0.5 mL of cell lysis buffer containing 1×
protease inhibitor cocktail II for 15 min on ice. Then,
the chromatin was isolated by adding 0.5 mL of nuclear
lysis buffer containing 1× protease inhibitor cocktail II,
followed by sonication to obtain sheared DNA. Chromatin
DNA fragments were diluted in 450 μL of dilution buffer
containing protease inhibitor cocktail II and precipitated
with antibodies against phospho-p53 (1:100) (Cell
Signaling Technology) or isotype control IgG including 20
μL of fully resuspended protein A/G magnetic beads at 4°C
overnight with rotation. Protein A/G magnetic beads were
precipitated with a magnetic separator and washed with low
salt, high salt, LiCl and TE Wash Buffer in sequence. Next,
the cross-linked protein/DNA complexes were reversed to
free DNA by incubating at 62°C for 2 h with shaking in
the presence of 100 μL of ChIP elution buffer and 1 μL
of proteinase K followed by incubation at 95°C for 10
min. Then, DNA was purified and used as a template for
PCR and real-time PCR using the following primer pairs:
5’-GGATAATTAGACGTACGTGGGC-3’ (forward) and
5’-GGACAATTGACAAAATCAGTATC-3’ (reverse) [63].
The PCR products were detected on a 2% agarose gel.

Genetic alterations in MM patients detected by
FISH
To evaluate the prognosis of MM patients, a FISH
kit was used to detect gene abnormalities in MM. The
kit can detect several common genetic abnormalities
in MM, including RB1 deletion, 13q14 deletion, 1q21
amplification and 14q32 translocation (Supplementary
Table 2). FISH was performed according to the
manufacturer’s instructions; the results were analyzed
using the ratio of the number of positive cells to the total
number of cells (counting for more than 200).

Statistical analysis
All samples were prepared in triplicate, and
experiments were repeated at least three times. The data
are presented as the means ± SD. Differences between
groups were evaluated using one-way ANOVA and
Student’s T test. P < 0.05 was considered statistically
significant.

Abbreviations
MM: Multiple myeloma; PCs: Plasma cells; BM:
bone marrow; ROS: Reactive oxygen species; DR:
Death receptors; TNF: Tumor necrosis factor receptor;
ER: Rndoplasmic reticulum; CAP: Cold atmospheric
plasma; MMP: Mitochondrial membrane potential; PAM:
Plasma-activated medium; MSC: Marrow stromal cells;
DBD: Dielectric barrier discharger; FDA: Food and drug
administration; RPMI: Roswell Park Memorial Institute;
siRNA: Short interfering RNAs; MFI: Mean fluorescence
intensity; SDS-PAGE: Sodium dodecyl sulfatepolyacrylamide gel electrophoresis; HRP: Horseradish

Preparation and analysis of MM clinical samples
Seven newly diagnosed MM patients were chosen
from the Department of Hematology, Xijing Hospital of
www.oncotarget.com

18014

Oncotarget

peroxidase; ChIP: Chromatin immunoprecipitation;
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